Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
TMCnet4d
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.
Endocrinology Advisor7d
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
PMLive7d
Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Clinical Pain Advisor12d
REDEFINE 2: Significant Weight Loss Observed With CagriSema vs Placebo in Patients With T2D
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Medical Dialogues12d
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Pharmabiz14d
Novo Nordisk announces results from REDEFINE 2 trial of CagriSema in people with obesity and type 2 diabetes
REDEFINE 2 is a 68 weeks efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The ...